Associated Papers
Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.
Mohammad AOA et al.
Cancer Biology & Therapy, 2025
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells.
Zheng Q et al.
Journal of the American Chemical Society, 2025
Natural human tRNAAla anticodon variants mistranslate the genetic code.
Tennakoon R et al.
Rna (new York, N.y.), 2025
XPO7 is a tumor suppressor regulating p21CIP1-dependent senescence.
Innes AJ et al.
Genes & Development, 2021
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Wang C et al.
Nature, 2019
Analyses on K-ras mutations and fascin expression in patients with cardia cancer.
Wei L et al.
Oncology Letters, 2019
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
Structure of Rap1b bound to talin reveals a pathway for triggering integrin activation.
Zhu L et al.
Nature Communications, 2017
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence.
Glück S et al.
Nature Cell Biology, 2017
Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W et al.
Oncotarget, 2017
Cellular model of neuronal atrophy induced by DYNC1I1 deficiency reveals protective roles of RAS-RAF-MEK signaling.
Liu ZD et al.
Protein & Cell, 2016
Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ et al.
Theranostics, 2016
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.
Rennert H et al.
Npj Genomic Medicine, 2016
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
Thompson KN et al.
Oncotarget, 2015
KANSL1 gene disruption associated with the full clinical spectrum of 17q21.31 microdeletion syndrome.
Moreno-Igoa M et al.
Bmc Medical Genetics, 2015
[KRAS gene somatic mutations in Chilean patients with colorectal cancer].
Hurtado C et al.
Revista Medica De Chile, 2014
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H et al.
The Journal of Clinical Investigation, 2011
BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness.
Wang Y et al.
Biochemical and Biophysical Research Communications, 2008
Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes.
Yanagida-Asanuma E et al.
The American Journal of Pathology, 2007
Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles.
Morcos P et al.
Molecular and Cellular Biology, 1996
Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells.
Waters AM et al.
Plos One, 0